Name: Impedimed (IPD) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

IPD

Health Care Equipment & Services

Impedimed

Short interest: <0.01%; −0.33 pp 30d; as of 2 July 2026
Reported shorts: 99.8K
Shares on issue: 3.660B

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Impedimed

Impedimed is a global leader in medical technology, specializing in the development and sale of devices using bioimpedance spectroscopy for noninvasive clinical assessment. The company focuses on addressing the challenges of secondary lymphedema, particularly related to breast cancer, through innovative solutions like the SOZO® Digital Health Platform. With operations in the US, Europe, and Australia, Impedimed is committed to improving patient outcomes by setting new standards of care.

Company profile →

Impedimed (ASX:IPD) has <0.01% of its shares on issue reported as short positions as of 2 July 2026, or about 99,795 shares. Over the past 30 days that figure has fallen 0.33 percentage points, and over 90 days it has fallen 0.58 percentage points. Its highest recorded short interest was 7.45% in May 2017. IPD is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 44, 2026.

Strategy fit

How each stock picker strategy reads IPD today

Zanger BreakoutWatchScore 14rank 1867 of 1890
CAN SLIMNot a candidate
Minervini Trend TemplateWatchScore 6rank 1642 of 1666
Crowded-Short BreakoutWatchScore 17rank 1292 of 1459
Quality compoundersWatchScore 9rank 1616 of 1750

Prices to 30 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

IPD fundamentals

In the year to 30 Jun 2026, Impedimed (ASX:IPD) recorded revenue of A$14.6M and a net loss after tax of A$24.9M. A year earlier it recorded revenue of A$12.7M and a net loss after tax of A$23.2M. Year-on-year growth: revenue +14.8% (FY). Net margin −170.4%, return on equity −162.4% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 29 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →